Back to search results

Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy

Abroad (travel likely)RecruitingPHASE2

Conditions

Recurrent Diffuse Large B-Cell Lymphoma · Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma · Refractory Diffuse Large B-Cell Lymphoma · Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • University of California Davis Comprehensive Cancer Center, Sacramento, California, United States

    Contact: Study coordinator (Office of Clinical Research) · OCRReferral@health.ucdavis.edu · 916-382-6970
    Contact: Principal Investigator (Joseph M. Tuscano, MD)
Study leads

  • Joseph M Tuscano, MD

    Principal Investigator

    University of California, Davis

View source on ClinicalTrials.gov(opens in a new tab)